Multiple Sclerosis

The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.

Latest News

multiple sclerosis diagnosis and biomarkers | Image credit: vegefox.com - stock.adobe.com
New Biomarkers Could Speed Up MS Diagnosis, Improve Care in US

July 18th 2025

New biomarkers enhance multiple sclerosis (MS) diagnosis, enabling earlier detection and improved patient care, transforming MS management across the health care system.

MS ribbon and brain drawing | Image credit: Pixel-Shot - stock.adobe.com
Review Highlights Gaps in Transition From Pediatric to Adult MS Care

July 16th 2025

Health care cure concept with a hand in blue medical gloves holding Coronavirus, Covid 19 virus, vaccine vial | Image credit: Leigh Prather - stock.adobe.com
Multinational Study Highlights COVID-19 Vaccine Safety in MS

July 8th 2025

man with mulitple sclerosis and walker | Image credit: chartphoto - stock.adobe.com
The Rise of Precision Monoclonal Antibodies in Treating MS

July 7th 2025

The MUSETTE trial did not meet its primary end point, suggesting a higher dose of IV ocrelizumab does not provide added benefits compared with the currently approved 600 mg dose. | Image credit: Chanintorn.v - stock.adobe.com
Higher-Dose Ocrelizumab Shows No Added Benefit vs Approved Dose in MS

April 9th 2025

Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain key insights into managing and understanding this condition.

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain valuable insights into managing and understanding this complex condition.
Continuing Medical Education
View All
July 19th 2025

The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of Early Intervention, Patient-Centered Care, and Disease-Modifying Therapies in Slowing Disease Progression

1.0 Credit / Neurology
July 19th 2025

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1.0 Credit / Immunology, Neurology
July 19th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 19th 2025

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

August 21, 2025 | 1:00 PM ET & 8:00 PM ET
July 19th 2025

Overview and Burden of Migraine

0.5 Credit / Neurology
July 19th 2025

The Role of the Pharmacist Migraine Management

0.5 Credit / Neurology
July 19th 2025

The Evolving Treatment Landscape of Migraine

0.5 Credit / Neurology
July 19th 2025

Leveraging Managed Care to Optimize Patient Outcomes: Integrating Novel Treatments in Schizophrenia

1.5 Credits / Neurology, Psychiatry
July 19th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

research results
February 24th 2021

Amiselimod Most Effective S1P Receptor Modulator for Patients With MS

Maggie L. Shaw
Among 6 sphingosine-1-phosphate (S1P) receptor modulators evaluated for use in patients with multiple sclerosis (MS), a new meta-analysis shows amiselimod had the highest efficacy.
Progressive MS Alliance Seeks Change to Study Designs to Spur New Therapies
February 20th 2021

Progressive MS Alliance Seeks Change to Study Designs to Spur New Therapies

Skylar Jeremias
Advocates for patients with progressive multiple sclerosis (MS) want changes in study designs on emerging therapies to speed development and better align with the needs of researchers and patients.
Close-up of syringe and vial
February 19th 2021

MS Society Releases Guidance on DMT Dosing Modifications for COVID-19 Vaccination

Jaime Rosenberg
The current guidance emphasizes that the mRNA-based Pfizer/BioNTech and Moderna vaccines are safe for people with multiple sclerosis (MS) taking disease modifying therapies (DMTs).
Dr Burcu Zeydan Explains How Aging Impacts Multiple Sclerosis
February 12th 2021

Dr Burcu Zeydan Explains How Aging Impacts Multiple Sclerosis

Timing of relapses in multiple sclerosis is one of several interactions among aging, the trajectory of progressive disease, and worsening disability, according to Burcu Zeydan, MD, assistant professor of neurology, assistant professor of radiology, at the Mayo Clinic.
Higher Rates of Medication Adherence Seen in MS Compared With Other Chronic Diseases
February 11th 2021

Higher Rates of Medication Adherence Seen in MS Compared With Other Chronic Diseases

Gianna Melillo
Compared with patients with Parkinson disease, rheumatoid arthritis, or epilepsy, those with multiple sclerosis exhibited higher rates of medication adherence throughout the first year of treatment.
Sunlight Exposure Linked to Reduced Disease Severity in MS
February 6th 2021

Sunlight Exposure Linked to Reduced Disease Severity in MS

Skylar Jeremias
Investigators observed that some patients had improvements in their multiple sclerosis (MS) severity with increased sun exposure, whereas photosensitive individuals and those taking certain medications did not see the same effects.
Peer-Led Education Improves Health Literacy More Than Lectures for Patients With MS
February 6th 2021

Peer-Led Education Improves Health Literacy More Than Lectures for Patients With MS

Skylar Jeremias
Peer-led education was found to have a greater impact on multiple sclerosis (MS) health literacy than lecture-based education, a recent study from Iran demonstrated.
Researchers Describe 5 Cognitive Phenotypes in Multiple Sclerosis
January 30th 2021

Researchers Describe 5 Cognitive Phenotypes in Multiple Sclerosis

Allison Inserro
The findings suggest that this new categorization of cognitive deficits in multiple sclerosis may support clinicians in treatment choices and help tailor cognitive rehabilitation strategies, the authors said.
Degraded myelin sheath
January 26th 2021

Ongoing Review of DMTs Necessary Among Patients With Multiple Sclerosis

Larry Hanover
Periodic review of treatment safety and monitoring are necessary as medical centers increasingly use newer disease-modifying therapies earlier in the course of multiple sclerosis.
Top 5 multiple sclerosis stories of 2020
December 27th 2020

Top 5 Most-Read Multiple Sclerosis Articles of 2020

Christina Mattina
The coronavirus disease 2019 (COVID-19) pandemic dominated headlines for much of 2020, and most of the top 5 multiple sclerosis articles of this year discussed the effects of COVID-19 on patients with this disease. Others touched on physician and patient assessments of relapse and potential new treatments for neural damage.
Researchers Review Available Efficacy, Safety Data on Ozanimod in RMS
December 23rd 2020

Researchers Review Available Efficacy, Safety Data on Ozanimod in RMS

Jaime Rosenberg
Researchers analyzed the available evidence on the treatment’s efficacy and safety profile from the RADIANCE and SUNBEAM trials.
SPMS Drug Linked to Improved Cognition Processing Speed, Study Says
December 19th 2020

SPMS Drug Linked to Improved Cognition Processing Speed, Study Says

Allison Inserro
As a neurodegenerative disease, secondary progressive multiple sclerosis (SPMS) may lead to a degradation of cognition skills as the disease progresses.
Cytokine Biomarkers Can Diagnose Multiple Sclerosis, Study Suggests
December 16th 2020

Cytokine Biomarkers Can Diagnose Multiple Sclerosis, Study Suggests

Jared Kaltwasser
A new study indicates that an analysis of serum and cerebrospinal fluid cytokine levels can identify multiple sclerosis and its forms.
Researchers Examine MS Gender Differences in Direct, Indirect Costs
December 12th 2020

Researchers Examine MS Gender Differences in Direct, Indirect Costs

Skylar Jeremias
The German multiple sclerosis (MS) study found differences by gender for some costs, but the overall economic burden of the disease was about the same.
Prevalence of Headache High in Patients With MS
December 12th 2020

Prevalence of Headache High in Patients With MS

AJMC Staff
A recent review examines the prevalence of headache among patients with multiple sclerosis, particularly migraine.
Study Probes Effect of Shared Decision-Making on MS Care in The Netherlands
December 5th 2020

Study Probes Effect of Shared Decision-Making on MS Care in The Netherlands

Allison Inserro
The Dutch study sought to add to what is known about the cost-effectiveness of shared decision-making in multiple sclerosis.
Dr Patricia Coyle
November 29th 2020

Dr Patricia Coyle on Considerations in Choosing a DMT for MS

Multiple factors come into play when providers and patients discuss a disease-modifying therapy for multiple sclerosis (MS), explains Patricia K. Coyle, MD, of Stony Brook University Neurosciences Institute.
New Study Finds Higher Incidence of Bladder Cancer, but Not Others, in MS
November 25th 2020

New Study Finds Higher Incidence of Bladder Cancer, but Not Others, in MS

Allison Inserro
Prior research has found increased colon and breast cancer in patients with multiple sclerosis (MS), but that was not borne out in this current study.
John Corboy, MD, University of Colorado Denver
November 23rd 2020

Dr John Corboy: The Jury Is Still Out on COVID-19 Risk for Patients With MS

Patients with multiple sclerosis (MS) may not have an increased risk of contracting coronavirus disease 2019 (COVID-19), explained John Corboy, MD, of the University of Colorado Denver, School of Medicine.
Pediatrics
November 20th 2020

Shift to Earlier Treatment, Access to More DMTs Improved Outcomes in Pediatric-Onset MS

Laura Joszt, MA
The shift to treat patients with pediatric-onset multiple sclerosis (POMS) who are treated earlier with a wider variety of medications has led to better outcomes, according to a recent study.
Dr Ruth Ann Marrie
November 17th 2020

Dr Ruth Ann Marrie on Comorbidities Affecting MS Treatment Decisions

Ruth Ann Marrie, MD, PhD, director of the Multiple Sclerosis Clinic at the University of Manitoba, discusses how comorbidities affect treatment and options for patients with multiple sclerosis (MS).
Swedish Study Examines Impact of Comorbidities on Cost of MS Over Time
November 13th 2020

Swedish Study Examines Impact of Comorbidities on Cost of MS Over Time

Allison Inserro
Which types of comorbidities have the greatest impact on direct and indirect costs of multiple sclerosis (MS) over time?
Dr Patricia Coyle
November 11th 2020

Dr Patricia Coyle on Escalation vs High-Efficacy Induction in MS

Patricia K. Coyle, MD, of Stony Brook University Neurosciences Institute, explains how studies are trying to answer a debate about 2 approaches to treat multiple sclerosis (MS).
Dr Ruth Ann Marrie
November 7th 2020

Dr Ruth Ann Marrie Discusses Comorbidities in Multiple Sclerosis

Ruth Ann Marrie, MD, PhD, director of the Multiple Sclerosis Clinic at the University of Manitoba, speaks about the overall prevalence of comorbidities in patients with multiple sclerosis (MS).
Woman in pain
November 7th 2020

Adverse Childhood Experiences More Common in MS, Study Says

AJMC Staff
The study sought to determine if 2 specific types of adverse childhood experiences, abuse and neglect, are linked with multiple sclerosis (MS) and other immune-mediated inflammatory diseases.
Damaged nerves
October 31st 2020

New Recommendations Open Door a Bit to Stem Cell Transplant for MS

AJMC Staff
The procedure might work best in patients who have had multiple sclerosis (MS) for less than 10 years, the report said.
John Corboy, MD, University of Colorado Denver
October 30th 2020

Dr John Corboy on Probing Patient Quality of Life Off Medication for MS

Quality of life for patients with multiple sclerosis (MS) could be better when they are off medication because they will not have adverse effects related to those medications, said John Corboy, MD, professor of neurology, University of Colorado Denver, School of Medicine.
Cell division
October 24th 2020

MS Research Examines PPD, Ozanimod in Pregnancy

AJMC Staff
Two abstracts presented at a recent multiple sclerosis meeting examined depression in pregnancy and pregnancy outcomes in ozanimod trials.
Infant
October 24th 2020

Pregnancy Can Delay MS Onset by 3 Years, Study Says

Allison Inserro
The researchers noted that although it is known that pregnancy is linked to reduced MS activity, the effect of pregnancy before MS diagnosis is unclear.
Study Findings Highlight Differences in MS Characteristics Between Sex, Disease Course
October 15th 2020

Study Findings Highlight Differences in MS Characteristics Between Sex, Disease Course

Jaime Rosenberg
Differences in clinical and demographic characteristics between men and women with multiple sclerosis (MS) are more prevalent regarding disease course than they are when stratifying by sex.
<1
...
34567891011
...
21>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo